Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-02-14

FDA Approved: SPIRIVA RESPIMAT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Spiriva Respimat tiotropium inhalation spray from Boehringer Ingelheim Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPIRIVA RESPIMAT (tiotropium bromide inhalation spray)

Snippet

SUPPL AP for SPIRIVA RESPIMAT (TIOTROPIUM BROMIDE INHALATION SPRAY)